Uncategorized
SanBio Granted Key Patent in Treatment for Macular Degeneration
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--SanBio, Inc., a scientific leader in regenerative medicine, today announced it has been granted a key patent by the United States Patent and Trademark Office (USPTO) covering its proprietary modified stem cells, SB623, for the treatment of retinal degeneration. SanBio developed SB623 to promote regenerative processes in the central nervous system and provide therapeutic options for debilitating neurological disorders, including retinal degeneration. Unite
